OncoNano Medicine, Inc.

We are excited to showcase the capabilities of our ON-BOARD™ platform with new data on IL-12 and TCE. #aacr2023

Thank you Dallas Innovates for spotlighting OncoNano and capturing our passion in working together to transform cancer therapeutics with our proprietary nanotechnology platform. https://lnkd.in/edijzkFP

While you may know how we are harnessing the power of nanotechnology with our ON-BOARD™ polymeric micelle platform to unlock a new era of targeted therapeutics, we want to take you behind the scenes and introduce the amazing people behind OncoNano. There’s no better way than starting with employee #1, Dr. Tian Zhao! Having co-invented the polymer technology in graduate school, today Tian serves as our Vice President, Research & Development. As the innovation catalyst at OncoNano, Tian guides the strategic vision and tactical execution of OncoNano’s discovery team and oversees early asset development. To learn more about Tian and our exciting pipeline advancing precise anti-cancer therapies, please visit: www.onconano.com.

Thank you Dallas Innovates for spotlighting OncoNano and capturing our passion in working together to transform cancer therapeutics with our proprietary nanotechnology platform. https://lnkd.in/edijzkFP

  Looking forward to Dr. Han’s oral presentation “Tumor Specific Delivery of Therapeutic Payloads Using an Ultra pH-Sensitive Nanoparticle Platform” at the Annual Congress of International Drug Discovery Science & Technology (IDDST) 2024.     OncoNano is pioneering the next frontier of cancer therapeutics using our proprietary nanotechnology platform. Our ON-BOARD™ platform exploits the highly acidic tumor microenvironment, a byproduct of cancer metabolism, to maximize the intratumoral delivery of its therapeutic cargoes. Learn how OncoNano is generating a robust oncology pipeline to advance more precise therapies and better patient outcomes. www.onconanomed.com #nanomedicine 

We look forward to seeing colleagues and partners at #ASCO24. Our CEO Kartik Krishnan and COO Melissa Paoloni will be in attendance so please reach out to connect.   Our team is pleased to share a Trials in Progress update on our ON-5001 study evaluating ONM-501, our dual-activating STING agonist, at the session below.    Please see the link to the press release on our website for additional information: https://lnkd.in/gn6jXhJS

OncoNano is sharing our most recent findings on the utility of the ON-BOARD™ platform to develop novel therapeutics for oncology patients. Data presented at the #AACR2024 describes the preclinical efficacy and tolerability of muONM-412, an ON-BOARD™ nanoparticle-encapsulated murine interleukin-12 fusion protein (IL-12Fc) and the in vitro characterization of ONM-412, encapsulating human IL-12Fc. Learn more about the results here. https://lnkd.in/gi-MRRMZ

We are looking forward to presenting Pre -Clinical novel data on IL-12 fusion protein encapsulated in ultra pH sensitive nanoparticles at AACR 2024 https://lnkd.in/dYcCpBcV

To enhance continued growth to develop innovative cancer therapies OncoNano Medicine is pleased to announce organization changes appointing Kartik Krishnan as CEO and Melissa Paoloni as a COO